StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the stock.
Separately, Benchmark restated a hold rating on shares of VolitionRx in a research note on Friday, August 16th.
Check Out Our Latest Stock Report on VolitionRx
VolitionRx Stock Performance
VolitionRx (NYSE:VNRX – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.34 million. As a group, equities analysts forecast that VolitionRx will post -0.31 earnings per share for the current year.
Insider Buying and Selling at VolitionRx
In other VolitionRx news, Director Guy Archibald Innes acquired 150,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were purchased at an average price of $0.67 per share, for a total transaction of $100,500.00. Following the completion of the purchase, the director now directly owns 406,683 shares of the company’s stock, valued at $272,477.61. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 12.80% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
- Five stocks we like better than VolitionRx
- Following Congress Stock Trades
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- 3 Fintech Stocks With Good 2021 Prospects
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- The Role Economic Reports Play in a Successful Investment Strategy
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.